{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:49:36Z","timestamp":1793155776937,"version":"4.5.0"},"reference-count":19,"publisher":"American Diabetes Association","issue":"3","funder":[{"DOI":"10.13039\/100007028","name":"Leona M. and Harry B. Helmsley Charitable Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007028","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,3,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>It is generally accepted that complete \u03b2-cell destruction eventually occurs in individuals with type 1 diabetes, which has implications for treatment approaches and insurance coverage. The frequency of residual insulin secretion in a large cohort of individuals at varying ages of diagnosis and type 1 diabetes duration is unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                    <jats:p>The frequency of residual insulin secretion was determined by measurement of nonfasting serum C-peptide concentration in 919 individuals with type 1 diabetes according to prespecified groups based on age at diagnosis and duration of disease (from 3 to 81 years' duration). Stimulated C-peptide was measured in those with detectable nonfasting values and a group of those with undetectable values as control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>The overall frequency of detectable nonfasting C-peptide was 29%, decreasing with time from diagnosis regardless of age at diagnosis. In all duration groups, the frequency of C-peptide was higher with diagnosis age &amp;gt;18 years compared with \u226418 years. Nineteen percent of those with undetectable nonfasting C-peptide were C-peptide positive upon stimulation testing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>The American Diabetes Association\u2019s definition of type 1 diabetes as \u201cusually leading to absolute insulin deficiency\u201d results in clinicians often considering the presence of residual insulin secretion as unexpected in this population. However, our data suggest that residual secretion is present in almost one out of three individuals 3 or more years from type 1 diabetes diagnosis. The frequency of residual C-peptide decreases with time from diagnosis regardless of age at diagnosis, yet at all durations of disease, diagnosis during adulthood is associated with greater frequency and higher values of C-peptide.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2337\/dc14-1952","type":"journal-article","created":{"date-parts":[[2014,12,18]],"date-time":"2014-12-18T15:25:37Z","timestamp":1418916337000},"page":"476-481","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":227,"title":["Prevalence of Detectable C-Peptide According to Age at Diagnosis and Duration of Type 1 Diabetes"],"prefix":"10.2337","volume":"38","author":[{"given":"Asa K.","family":"Davis","sequence":"first","affiliation":[{"name":"Benaroya Research Institute, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie N.","family":"DuBose","sequence":"additional","affiliation":[{"name":"Jaeb Center for Health Research, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Haller","sequence":"additional","affiliation":[{"name":"University of Florida, Gainesville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kellee M.","family":"Miller","sequence":"additional","affiliation":[{"name":"Jaeb Center for Health Research, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda A.","family":"DiMeglio","sequence":"additional","affiliation":[{"name":"Indiana University School of Medicine, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen E.","family":"Bethin","sequence":"additional","affiliation":[{"name":"School of Medicine and Biomedical Sciences at the University at Buffalo, The State University of New York, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin S.","family":"Goland","sequence":"additional","affiliation":[{"name":"Naomi Berrie Diabetes Center at Columbia University, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen M.","family":"Greenberg","sequence":"additional","affiliation":[{"name":"Naomi Berrie Diabetes Center at Columbia University, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Liljenquist","sequence":"additional","affiliation":[{"name":"Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, ID"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Ahmann","sequence":"additional","affiliation":[{"name":"Harold Schnitzer Diabetes Health Center, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santica M.","family":"Marcovina","sequence":"additional","affiliation":[{"name":"Northwest Lipid Metabolism and Diabetes Research Laboratories, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne L.","family":"Peters","sequence":"additional","affiliation":[{"name":"Keck School of Medicine of the University of Southern California, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy W.","family":"Beck","sequence":"additional","affiliation":[{"name":"Jaeb Center for Health Research, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla J.","family":"Greenbaum","sequence":"additional","affiliation":[{"name":"Benaroya Research Institute, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2014,12,17]]},"reference":[{"key":"2022031301341419400_B1","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/dmrr.943","article-title":"C-peptide in the natural history of type 1 diabetes","volume":"25","author":"Palmer","year":"2009","journal-title":"Diabetes Metab Res Rev"},{"key":"2022031301341419400_B2","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/dme.12159","article-title":"The clinical utility of C-peptide measurement in the care of patients with diabetes","volume":"30","author":"Jones","year":"2013","journal-title":"Diabet Med"},{"key":"2022031301341419400_B3","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.2337\/dc07-2451","article-title":"Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes","volume":"31","author":"Greenbaum","year":"2008","journal-title":"Diabetes Care"},{"key":"2022031301341419400_B4","doi-asserted-by":"crossref","first-page":"250","DOI":"10.2337\/diabetes.53.1.250","article-title":"C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001","volume":"53","author":"Palmer","year":"2004","journal-title":"Diabetes"},{"key":"2022031301341419400_B5","doi-asserted-by":"crossref","first-page":"832","DOI":"10.2337\/diacare.26.3.832","article-title":"Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial","volume":"26","author":"Steffes","year":"2003","journal-title":"Diabetes Care"},{"key":"2022031301341419400_B6","article-title":"Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial","author":"Lachin","journal-title":"Diabetes"},{"key":"2022031301341419400_B7","doi-asserted-by":"crossref","first-page":"E2078","DOI":"10.1210\/jc.2012-2115","article-title":"Continuous glucose monitoring after islet transplantation in type 1 diabetes: an excellent graft function (\u03b2-score greater than 7) Is required to abrogate hyperglycemia, whereas a minimal function is necessary to suppress severe hypoglycemia (\u03b2-score greater than 3)","volume":"97","author":"Vantyghem","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031301341419400_B8","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.2337\/db11-1538","article-title":"Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data","volume":"61","author":"Greenbaum","year":"2012","journal-title":"Diabetes"},{"key":"2022031301341419400_B9","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.diabres.2013.03.003","article-title":"Decline of C-peptide during the first year after diagnosis of Type 1 diabetes in children and adolescents","volume":"100","author":"Ludvigsson","year":"2013","journal-title":"Diabetes Res Clin Pract"},{"key":"2022031301341419400_B10","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.2337\/db10-0676","article-title":"Residual insulin production and pancreatic \u03b2-cell turnover after 50 years of diabetes: Joslin Medalist Study","volume":"59","author":"Keenan","year":"2010","journal-title":"Diabetes"},{"key":"2022031301341419400_B11","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1111\/dme.12504","article-title":"Insulin secretion measured by stimulated C-peptide in long-established Type 1 diabetes in the Diabetes Control and Complications Trial (DCCT)\/ Epidemiology of Diabetes Interventions and Complications (EDIC) cohort: a pilot study","volume":"31","author":"McGee","year":"2014","journal-title":"Diabet Med"},{"key":"2022031301341419400_B12","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.2337\/dc08-2326","article-title":"Preservation of beta-cell function in autoantibody-positive youth with diabetes","volume":"32","author":"Greenbaum","year":"2009","journal-title":"Diabetes Care"},{"key":"2022031301341419400_B13","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1007\/s00125-012-2719-6","article-title":"Clinical evolution of beta cell function in youth with diabetes: the SEARCH for Diabetes in Youth study","volume":"55","author":"Dabelea","year":"2012","journal-title":"Diabetologia"},{"key":"2022031301341419400_B14","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00125-013-3067-x","article-title":"The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells","volume":"57","author":"Oram","year":"2014","journal-title":"Diabetologia"},{"key":"2022031301341419400_B15","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/dom.12216","article-title":"Age-dependent decline of \u03b2-cell function in type 1 diabetes after diagnosis: a multi-centre longitudinal study","volume":"16","author":"Barker","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"2022031301341419400_B16","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1210\/jc.2012-1561","article-title":"The T1D Exchange clinic registry","volume":"97","author":"Beck","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031301341419400_B17","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.2337\/dc14-S014","article-title":"Standards of medical care in diabetes\u20142014","volume":"37","author":"American Diabetes Association","year":"2014","journal-title":"Diabetes Care"},{"key":"2022031301341419400_B18","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2337\/dc11-1236","article-title":"Persistence of prolonged C-peptide production in type 1 diabetes as measured with an ultrasensitive C-peptide assay","volume":"35","author":"Wang","year":"2012","journal-title":"Diabetes Care"},{"key":"2022031301341419400_B19","unstructured":"Decision Memo for Insulin Pump: C-Peptide Levels as a Criterion for Use (CAG-00092R) [Internet], 2004. Washington, DC, Centers for Medicare and Medicaid Services. Available from http:\/\/www.cms.gov\/medicare-coverage-database\/details\/nca-decision-memo.aspx?NCAId=109&IsPopup=y&NCDId=223&NcaName=Insulin+Pump*3a$+C-Peptide+Levels+as+a+Criterion+for+Use&ncdver=2&bc=AAAAAAAACAAAAA%3D%3D&. Accessed 3 April 2014"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/care.diabetesjournals.org\/syndication\/doi\/10.2337\/dc14-1952","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/38\/3\/476\/623884\/dc141952.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/38\/3\/476\/623884\/dc141952.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T00:27:26Z","timestamp":1647131246000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/38\/3\/476\/37608\/Prevalence-of-Detectable-C-Peptide-According-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,17]]},"references-count":19,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2014,12,17]]},"published-print":{"date-parts":[[2015,3,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc14-1952","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,17]]}}}